Cancer cells can lie dormant for years. Hiding in bone marrow and tissue, they escape detection while doctors declare patients cancer-free. Then one day, without warning, those sleeping cells wake up. Cancer returns. Treatment starts over. Only now there’s no cure.
What if doctors could find those hidden cells and kill them before they reactivate? A team at the University of Pennsylvania just proved it’s possible. Using drugs already approved for other conditions, researchers eliminated dormant cancer cells in 80 percent of breast cancer survivors. After three years, patients who got both medications showed zero recurrence. None.
Results from this federally funded trial, published in Nature Medicine, offer something breast cancer survivors rarely get after finishing treatment. Hope that cancer won’t come back. A way to fight the invisible enemy before it strikes again.
Breast Cancer Relapse Remains Major Threat
Survival rates for breast cancer keep getting better. Earlier detection catches tumors when they’re smaller. New treatments work better with fewer side effects. More people beat their diagnosis than ever before.
Yet roughly 30 percent of patients still face recurrence. When breast cancer returns after initial treatment, doctors can manage it but cannot cure it. Patients go on continuous therapy that never ends and never eliminates the disease. Treatment becomes a permanent part of life.
Different breast cancer subtypes follow different patterns. Triple-negative and HER2-positive cancers tend to recur within a few years. ER-positive tumors can stay quiet for decades before suddenly returning. Until now, oncologists had no method for predicting which survivors harbored cells that would eventually cause relapse. Patients finished treatment and waited. Hoping. Wondering. Living with fear.
Sleeper Cells Hide in Your Body After Treatment
Surgery removes tumors. Chemotherapy kills rapidly dividing cells. Radiation destroys cancer at specific sites. Scans come back clear. Blood tests look normal. Doctors declare no evidence of disease.
Yet some cancer cells survive by going dormant. Scientists call them disseminated tumor cells or minimal residual disease. MRD sounds technical, but it means something simple. Cancer cells are scattered in small numbers throughout the body, hiding in bone marrow and other tissues.
Sleeper cells differ from active cancer. Regular imaging tests cannot spot them because they’re not growing or multiplying. They exist in a suspended state, metabolically quiet, waiting. Some stay dormant for months. Others sleep for years or decades.
Why Dormant Cells Eventually Wake Up
Nobody knows exactly what triggers reactivation. Cells that lie quietly suddenly begin dividing again. They multiply. Enter the bloodstream. Travel to other organs. Metastatic breast cancer develops from these awakened cells.
Patients with detectable MRD face a much higher recurrence risk compared to those without dormant cells. Their overall survival rates drop. Yet standard practice offers no way to eliminate MRD before it causes problems. Doctors can only watch and wait, scanning every few months, hoping nothing shows up.
Penn Medicine Team Cracks Dormant Cell Mystery
Lewis Chodosh chairs the Department of Cancer Biology at Penn’s Perelman School of Medicine. His lab spent years studying how dormant tumor cells manage to survive in patients for such long periods. What allows them to persist when treatment kills active cancer?
Research revealed that dormant cells operate under completely different biological rules than growing tumors. Chodosh explained, “Our research shows that this sleeper phase represents an opportunity to intervene and eradicate the dormant tumor cells before they have the chance to come back as aggressive, metastatic disease. Surprisingly, we’ve found that certain drugs that don’t work against actively growing cancers can be very effective against these sleeper cells. This tells us that the biology of dormant tumor cells is very different from active cancer cells.”
Finding that distinction opened new possibilities. If dormant cells behave differently, maybe different drugs could target them. Medications that fail against active tumors might work against sleeping ones.
Mouse Studies Revealed Treatment Strategy
Chodosh’s team conducted experiments using mouse models. Mice received breast cancer treatment that left behind dormant tumor cells, mimicking what happens in human patients. Scientists then tested various drug combinations to see which ones could eliminate MRD.
Two types of medications showed promise. Both had FDA approval for treating other medical conditions, meaning safety profiles were already established. One drug type inhibited autophagy, a cellular recycling process. Another blocked mTOR signaling, a pathway involved in cell growth.
Results in mice looked good. Drugs cleared minimal residual disease and extended survival without recurrence. Animals treated with these medications lived longer than untreated mice harboring dormant cells. Research identified autophagy and mTOR signaling as key mechanisms allowing tumor cells to maintain dormancy.
Bone Marrow Tests Identify High Risk Survivors
Angela DeMichele leads breast cancer research at Penn’s Abramson Cancer Center. She partnered with Chodosh to translate laboratory findings into human trials. The first step was screening. Could doctors identify which breast cancer survivors had dormant cells?
DeMichele’s team enrolled survivors who had finished treatment within the previous five years. All had clear scans showing no evidence of active disease. Researchers performed bone marrow aspirates, extracting small samples to examine under microscopes.
Tests found dormant tumor cells in many patients despite normal imaging. Simply being in remission didn’t guarantee the absence of sleeping cancer cells. Some survivors had them. Others didn’t. Screening separated high-risk from lower-risk patients.
CLEVER Trial Tests Drugs on 51 Patients
Survivors found to have detectable dormant cells became eligible for the CLEVER clinical trial. Federally funded through grants from the National Cancer Institute and the Department of Defense, the phase II study randomly assigned 51 participants to one of three treatment groups.
Fifteen patients received hydroxychloroquine alone. Another fifteen got everolimus by itself. Twenty-one received both medications together. All three groups underwent six cycles of treatment spanning several months.
Hydroxychloroquine, commonly known as HCQ, inhibits autophagy. Doctors prescribe it for malaria and certain autoimmune conditions. Everolimus, abbreviated EVE, blocks mTOR signaling. Transplant patients take it to prevent organ rejection.
Repurposing existing medications meant researchers knew what side effects to expect. Patients didn’t face unknown risks from experimental compounds. Safety data already existed.
80 Percent of Patients Had Cells Cleared
Treatment worked. After six to twelve months on study drugs, bone marrow testing showed dormant tumor cells had disappeared in most participants. Statistical analysis revealed posterior probabilities between 98 and 99.9 percent that three cycles of HCQ, EVE, or their combination led to reduced or undetectable disseminated tumor cells compared to no treatment.
Drug regimens achieved estimated reductions of 80 percent for HCQ alone, 78 percent for EVE alone, and 87 percent for combination therapy. Numbers backed up what researchers hoped to find. Targeting dormant cells with appropriate medications depleted minimal residual disease.
Only one patient discontinued treatment early due to side effects. Otherwise, participants tolerated the drugs well. Feasibility proved good. Safety looked acceptable. Primary endpoints for a phase II trial were met.
Three Year Survival Rates Exceed Expectations
Following patients over time revealed even better news. At median follow-up of 42 months, landmark three-year survival without any disease recurrence hit 91.7 percent in the HCQ group and 92.9 percent in the EVE group. Combination therapy patients showed 100 percent survival. Every single person who got both drugs remained cancer-free.
Among all participants, only two experienced recurrence during the study period. Both had been in single-drug groups. Patients who successfully cleared dormant cells from their bone marrow had much better outcomes. Hazard ratio calculations showed 79 percent lower risk of recurrence for those who cleared cells versus those who didn’t.
Results suggested that reducing residual tumor cell burden directly improved recurrence-free survival. Fewer dormant cells meant a lower chance of relapse. Kill the sleeper cells before they wake up, and cancer may never return.
Wait and See Approach No Longer Only Option
Current standard practice after breast cancer treatment offers surveillance but not prevention. Patients get regular imaging and blood tests, watching for signs of recurrence. If cancer comes back, treatment starts again. Nothing stops relapse before it happens.
DeMichele described the problem survivors face. “The lingering fear of cancer returning is something that hangs over many breast cancer survivors after they celebrate the end of treatment. Right now, we just don’t know when or if someone’s cancer will come back—that’s the problem we set out to solve. Our study shows that preventing recurrence by monitoring and targeting dormant tumor cells is a strategy that holds real promise, and I hope it ignites more research in this area.”
CLEVER trial results provide proof of concept that intervention is possible. Screen for dormant cells. Treat patients who have them. Monitor to confirm clearance. Prevent recurrence rather than managing it after the fact.
DeMichele added, “We want to be able to give patients a better option than ‘wait and see’ after they complete breast cancer treatment. We’re encouraged by these results that we’re on the right track.”
Larger Trials Already Enrolling Patients
Phase II studies establish feasibility and generate preliminary efficacy data. They don’t provide definitive proof. Larger phase III trials with more patients and longer follow-up are needed to confirm findings and change standard treatment guidelines.
Penn Medicine researchers have already launched two additional studies. ABBY clinical trial and PALAVY clinical trial are both phase II trials that expand on CLEVER results. Multiple cancer centers across the country are now enrolling participants.
Studies will recruit more breast cancer survivors, test the same drug combinations, and track outcomes over longer periods. If results match or exceed what CLEVER showed, medical practice could shift toward screening all breast cancer survivors for minimal residual disease and treating those who test positive.
New Era in Breast Cancer Survivorship
Nobody enjoys bone marrow aspiration. Extracting samples from bone marrow hurts. Taking medications for months carries side effects. Yet compared to living with constant fear of recurrence or facing incurable metastatic disease, temporary discomfort becomes acceptable.
CLEVER trial enrolled only 51 patients. The sample size was small. Follow-up time was relatively short at 42 months. Longer observation will determine whether benefits persist beyond three years. Some ER-positive breast cancers recur a decade or more after initial diagnosis.
Still, proof of concept matters. Showing that dormant tumor cells can be detected, targeted, and eliminated establishes a new treatment paradigm. Breast cancer survivorship may soon include routine MRD screening and preventive therapy for high-risk patients.
Results demonstrate that medications work differently against dormant versus active cancer cells. Future research might identify even better drug combinations specifically designed to target minimal residual disease. Understanding the unique biology of sleeper cells opens multiple avenues for intervention.
Survivors deserve better than endless waiting. Fear of recurrence affects quality of life, mental health, and long-term planning. Being able to measure actual risk rather than just statistical probability gives both doctors and patients concrete information to guide decisions.
Cancer cells that hide in bone marrow can’t hide anymore. Drugs that put them to sleep permanently may soon become standard care. Breast cancer survivors might finally get what they need most after finishing treatment. Actual prevention instead of anxious hope.
